AstraZeneca to face Crestor generic challenge

Published: 2009-11-16 07:00:00

Updated: 2009-11-16 07:00:00

The Britain-based AstaZeneca is expected to face a generic challenge to its blockbuster cholesterol drug Crestor (rosuvastatin calcium) by 50 Korean companies.

These local companies are seeking approval to sell a copycat version of Crestor aiming to launch its version in December as its re-exa...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK